{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:33:12Z","timestamp":1789695192935,"version":"4.0.1"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T00:00:00Z","timestamp":1363651200000},"content-version":"vor","delay-in-days":11450,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1981,11,12]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> The steps in the evolution of sulfamoyl diuretics in current clinical use are outlined. The development was initiated by the chance observation of a clinical side effect of sulfanilamide, which became the first sulfamoyl group (\u2010SO<jats:sub>2<\/jats:sub>NH<jats:sub>2<\/jats:sub>)\u2010bearing compound used for diuretic treatment of patients. Ensuing chemical synthesis over the past three decades led to the development of three types of sulfamoyl diuretics: carbonic anhydrase inhibitors, thiazides, and the loop or high\u2010ceiling saluretic agents represented by furosemide and bumetanide. The structural relationship of furosemide to sulfanilamide and the thiazide\u2010type diuretics and, for bumetanide, the more specific structure for loop diuretic activity are discussed.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1981.tb05661.x","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T11:27:21Z","timestamp":1363692441000},"page":"531-536","source":"Crossref","is-referenced-by-count":22,"title":["Bumetanide\u2014The Way to Its Chemical Structure"],"prefix":"10.1002","volume":"21","author":[{"given":"PETER W.","family":"FEIT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-36-9115P"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-48-13218"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/146164a0"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/ajplegacy.1945.144.2.239","article-title":"The nature of the renal tubular mechanism for acidifying the urine","volume":"144","author":"Pitts RF","year":"1945","journal-title":"Am J Physiol."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM194902032400503"},{"key":"e_1_2_1_7_2","first-page":"303","article-title":"An historical account of CO2 chemistry and the development of carbonic anhydrase inhibitors","volume":"21","author":"Maren TH","year":"1979","journal-title":"Pharmacologist."},{"key":"e_1_2_1_8_2","first-page":"97","article-title":"Factors basic to the development of useful inhibitors of renal transport mechanisms","volume":"98","author":"Beyer KH","year":"1954","journal-title":"Arch Int Pharmacodyn."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1958.tb54606.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1958.tb54609.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja01565a079"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02327380"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1959.tb01177.x"},{"key":"e_1_2_1_14_2","first-page":"257","volume-title":"Diuretics, Handbook of Experimental Pharmacology","author":"Peters G","year":"1969"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1112283"},{"key":"e_1_2_1_16_2","first-page":"44","article-title":"Die salidiuretische Wirksamkeit der Chlor\u2010N\u2010(2\u2010furylmethyl)\u20105\u2010sulfamyl\u2010anthranils\u00e4ure","volume":"14","author":"Muschaweck R","year":"1964","journal-title":"Arzneim-Forsch."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1974156588"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00287a014"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00271a021"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00260a010"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00268a022"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00235a010"},{"issue":"6","key":"e_1_2_1_23_2","first-page":"7","article-title":"Eds. Bumetanide","volume":"51","author":"Hoffbrand BI","year":"1975","journal-title":"Postgrad Med J."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00274a037"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1981.tb05661.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1981.tb05661.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T04:09:37Z","timestamp":1698811777000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1981.tb05661.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,11,12]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1981,11,12]]}},"alternative-id":["10.1002\/j.1552-4604.1981.tb05661.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1981.tb05661.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,11,12]]}}}